Haleon’s (HLN) Sell Rating Reaffirmed at Deutsche Bank Aktiengesellschaft

Haleon (LON:HLN)‘s stock had its “sell” rating reissued by investment analysts at Deutsche Bank Aktiengesellschaft in a research report issued on Wednesday,Digital Look reports. They currently have a GBX 325 price objective on the stock. Deutsche Bank Aktiengesellschaft’s price target would indicate a potential downside of 7.35% from the company’s previous close.

A number of other brokerages also recently weighed in on HLN. Berenberg Bank reiterated a “buy” rating and issued a GBX 512 price target on shares of Haleon in a research report on Thursday, April 30th. JPMorgan Chase & Co. decreased their price objective on shares of Haleon from GBX 335 to GBX 315 and set an “underweight” rating for the company in a report on Thursday, June 25th. Jefferies Financial Group lowered their target price on shares of Haleon from GBX 450 to GBX 400 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and issued a GBX 370 target price on shares of Haleon in a report on Thursday, April 30th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of GBX 393.67.

Haleon Trading Up 0.9%

HLN traded up GBX 3.10 during midday trading on Wednesday, reaching GBX 350.80. 142,179,078 shares of the company were exchanged, compared to its average volume of 30,300,482. The stock has a market capitalization of £31.04 billion, a P/E ratio of 18.96, a PEG ratio of 1.49 and a beta of 0.25. Haleon has a one year low of GBX 317.80 and a one year high of GBX 416.10. The stock’s 50-day simple moving average is GBX 338.29 and its 200 day simple moving average is GBX 363.90. The company has a debt-to-equity ratio of 52.26, a quick ratio of 0.93 and a current ratio of 0.92.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.